Opthea Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume504,572 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive OPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

About Opthea

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Opthea (ASX:OPT) Frequently Asked Questions

What stocks does MarketBeat like better than Opthea?

Wall Street analysts have given Opthea a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Opthea wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Opthea's earnings last quarter?

Opthea Limited (ASX:OPT) announced its quarterly earnings data on Friday, August, 9th. The company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.00.
View Opthea's earnings history

Who are Opthea's key executives?

Opthea's management team includes the following people:
  • Dr. Megan Baldwin M.A.I.C.D., Ph.D., MAICD, MD, CEO & Exec. Director (Age 46, Pay $591.3k)
  • Mr. Michael Tonroe B.Sc., F.C.A., M.A.I.C.D., Bsc(Hons), ACA, MAICD, CFO & Company Sec. (Age 54, Pay $351.56k)
  • Ms. Annie Lee, Fin. & Operations Mang.
  • Dr. Richard Chadwick, Head of Intellectual Property (Age 55)
  • Dr. Michael Gerometta, Head of Chemistry, Manufacturing & Controls Devel. (Age 57)
  • Dr. Ian Leitch, Director of Clinical Research (Age 58)
  • Dr. James Goding, Independent Consultant

Who are some of Opthea's key competitors?

What other stocks do shareholders of Opthea own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opthea investors own include The Walt Disney (DIS), Datadog (DDOG), (CRM), (CGC), Berkshire Hathaway (BRK.B), (AZN), American Water Works (AWK), Activision Blizzard (ATVI), Appian (APPN) and Advanced Micro Devices (AMD).

What is Opthea's stock symbol?

Opthea trades on the ASX under the ticker symbol "OPT."

How much money does Opthea make?

Opthea has a market capitalization of $0.00 and generates $95,563.00 in revenue each year.

What is Opthea's official website?

The official website for Opthea is

Where are Opthea's headquarters?

Opthea is headquartered at Se 403 L 4, Melbourne, Victoria 3141.

How can I contact Opthea?

Opthea's mailing address is Se 403 L 4, Melbourne, Victoria 3141. The company can be reached via phone at 61 3 9826 0399.

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.